@article{3219378,
    title = "Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event",
    author = "Syrigos, N. and Kollias, A. and Grapsa, D. and Fyta, E. and Kyriakoulis, K.G. and Vathiotis, I. and Kotteas, E. and Syrigou, E.",
    journal = "Vaccine",
    year = "2022",
    volume = "10",
    number = "5",
    publisher = "MDPI",
    issn = "0264-410X",
    doi = "10.3390/vaccines10050745",
    abstract = "This brief report examined the frequency and characteristics of a significant blood-pressure (BP) increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers who were advised to measure their BP at home. A total of 797 participants (mean age 48.1 ± 10.8 years, 63% women, 39% smokers) were included in the analysis. Seven participants reported an increase in their BP (three in the range of grade 2 and four in the range of grade 3 hypertension). Only one participant had a history of treated hypertension. The BP increase was observed at the end of the first week after the first dose, lasted for 3 to 4 days, and recurred promptly after the second dose. Only one case required hospitalization, mainly due to a history of cardiovascular disease (follow-up). Individuals experiencing a BP increase compared with those not reporting issues with their BP had a higher mean age and similar distribution of sex and non-smoking status. In conclusion, a significant BP increase after Pfizer-BioNTech vaccination seems to be rare and of a benign and transient nature. Monitoring the BP before and after vaccination might be advisable only for selected individuals with a high cardiovascular risk. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}